drugset / Trial / NCT01787383

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

NCT01787383

Phase 3 Completed 200 enrolled LEO Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this trial is to evaluate the safety of a simultaneous treatment regimen compared to a sequential treatment regimen when two separate areas with AKs (one located on face/scalp and the other located on trunk/ extremities) are treated with ingenol mebutate gel

Timeline

Start
2013-02
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator ingenol mebutate Small molecule 0.015 %
Comparator ingenol mebutate Small molecule 0.05 %

Indications